Psoriasis: FDA reporting patterns
129,019 FDA FAERS reports mention Psoriasis. 47,059 reports have a serious outcome flag.
Medicines named as suspect
- Etanercept: 24,348 reports
- Adalimumab: 24,092 reports
- Secukinumab: 22,338 reports
- Apremilast: 19,652 reports
- Risankizumab: 7,866 reports
- Methotrexate: 6,716 reports
- Ustekinumab: 5,512 reports
- Infliximab: 4,853 reports
- Certolizumab Pegol: 3,836 reports
- Ixekizumab: 2,945 reports
- Bimekizumab: 2,629 reports
- Dupilumab: 2,475 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.